Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dillon

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Hemasphere|August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive inductionKonstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
Leukemia|May 23, 2024
Recommendations from the AML molecular MRD expert advisory boardStuart Scott, Alison Devonshire, Richard Dillon, et al.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Blood Advances|September 9, 2022
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disordersPatrick Harrington, Ashwini Kurshan, Marc Delord, et al.
American Journal of Hematology|September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panelFarhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Blood|September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemiaSun Loo, Nicola Potter, Adam Ivey, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Blood Advances|October 25, 2019
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemiaPaul Milne, Charlotte Wilhelm-Benartzi, Michael R Grunwald, et al.
Hemasphere|August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive inductionKonstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
Leukemia|May 23, 2024
Recommendations from the AML molecular MRD expert advisory boardStuart Scott, Alison Devonshire, Richard Dillon, et al.
British Journal of Haematology|May 28, 2020
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemiaIng S Tiong, Richard Dillon, Adam Ivey, et al.
Blood Advances|September 9, 2022
Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disordersPatrick Harrington, Ashwini Kurshan, Marc Delord, et al.
American Journal of Hematology|September 6, 2023
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panelFarhad Ravandi, Jacqueline Cloos, Francesco Buccisano, et al.
Blood Advances|February 18, 2021
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signatureSamah Alimam, William Villiers, Richard Dillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman, et al.
Blood|February 16, 2024
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionJad Othman, Nicola Potter, Adam Ivey, et al.
Blood|September 24, 2024
Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemiaSun Loo, Nicola Potter, Adam Ivey, et al.
Pageof 11